Clinical Trial Update: Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315 [Phase 2]

View source ↗

Summary

Phase 2 follow-up study assessing immunologic and virologic effects of long-term HAART in moderately advanced HIV-1 disease (ACTG 315 follow-up).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 2 | Status: COMPLETED